A new study involving lixisenatide, an approved GLP-1 receptor agonist, was published on October 3, 2026. The publication, titled "Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study," appeared in the Journal of the European Academy of Dermatology and Venereology (JEADV). The study examined GLP-1 receptor agonists, a drug class that includes lixisenatide, in the context of hidradenitis suppurativa using a nationwide cohort design. No specific findings, outcomes, or conclusions from the study have been detailed in the available event data. The publication is listed under PubMed ID 42828450. This entry reflects the release of the publication itself rather than any reported results. Readers interested in the specifics of the study design, population, or outcomes should consult the full text through the provided source link. For general background on lixisenatide, its approved status, and its pharmacological class, readers can refer to the compound overview.
Lixisenatide Studied in New GLP-1/Hidradenitis Suppurativa Publication
See the full lixisenatide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42828450/